PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013

Major biopharmaceutical companies with substantial internal mammalian cell culture capability are forecast to have adequate internal manufacturing capacity. Contract mammalian cell culture manufacturers (CMOs) however, are likely to feel the pressure of increased utilization rates. For these CMOs and biopharmaceutical companies depending on them, understanding critical demand drivers, market factors and manufacturing trends is instrumental to making effective strategic supply decisions.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Fairfax, VA (PRWEB) December 2, 2008

Major biopharmaceutical companies with substantial internal mammalian cell culture capability are forecast to have adequate internal manufacturing capacity. Contract mammalian cell culture manufacturers (CMOs) however, are likely to feel the pressure of increased utilization rates. For these CMOs and biopharmaceutical companies depending on them, understanding critical demand drivers, market factors and manufacturing trends is instrumental to making effective strategic supply decisions.

"Cell Culture Manufacturing Capacity: Trends and Outlook through 2013" provides a timely and detailed examination of these issues. In this definitive report, foremost experts BioProcess Technology Consultants and PharmSource Information Services provide an extensive supply and demand analysis in addition to in-depth recommendations for the cell culture industry. Detailed data points include: product pipeline analysis, probable product success rates, time to market, API requirements, current and planned capacity, process yields and the potential impact of technology advances including biosimilars. "This report offers valuable strategic insight to support critical 'make or buy' decisions for mammalian cell culture manufacturers, key recommendations for capital investments and clear pricing strategy direction for the biologics contract manufacturing industry," comments BioProcess Technology Consultants president and founder Howard L. Levine, Ph.D. PharmSource president and founder, Jim Miller, concurs, "At a time of so much uncertainty in the biopharmaceutical industry, this analysis provides decision makers with the in-depth understanding they need to may critical API supply decisions."

The $4,950 report will be offered at the $700 pre-order discount price of $4,250 through December 15, 2008. For more detailed information and ordering instructions visit: http://www.pharmsource.com/forms.cfm?id=32.

About the Authors:
Founded in 1994, BioProcess Technology Consultants, Inc. is the leading providers of strategic, technical, operational, and regulatory consulting services to the biopharmaceutical industry and the industry's foremost expert on cell culture manufacturing. The company specializes in helping clients speed their products from clone to commercial®. Visit BioProcess Technology Consultants on the web at http://www.bioprocessconsultants.com or contact them at 978-266-9113.

PharmSource Information Services, Inc. is a respected provider of contract drug development and manufacturing intelligence. Since 1996 PharmSource has assisted Biotechnology and Pharmaceutical companies with the implementation and management of sourcing strategies and tactics through insightful publications, analyses and intelligence services. Visit PharmSource on the web at http://www.pharmsource.com or contact them at 703-383-4903.

###


Contact